Anthony Yazbeck: Why the Hemolysin Test Matters More Than You Think
Anthony Yazbeck, Application Specialist at Atom Medical-Dora, shared a post on LinkedIn:
”Why the Hemolysin Test Matters More Than You Think
In transfusion medicine, compatibility goes beyond ABO typing — and this is where the hemolysin test becomes critical.
Hemolysins are antibodies capable of destroying red blood cells, particularly anti-A and anti-B, which play a major role in non-identical (non-iso) group transfusions.
Why does this matter?
In group O donors, plasma may contain anti-A and anti-B antibodies. When transfused into A, B, or AB recipients, these antibodies can attack the recipient’s red blood cells, leading to hemolytic transfusion reactions.
While antibody titration is often used to assess risk, it only measures the quantity of antibodies — not their ability to cause damage.
The real clinical concern lies in hemolysins: antibodies that can actively activate complement and destroy red blood cells.
This is why hemolysin testing is essential:
- Detects clinically significant anti-A and anti-B hemolysins
- Adds functional insight beyond antibody titers
- Reduces risk in non-iso group transfusions
- Strengthens donor selection and blood safety
In resource-limited settings, overlooking this step can increase transfusion risks. Strengthening awareness and implementation of hemolysin screening can make a life-saving difference.
Safe blood isn’t just about how much antibody is present — but what it can do.”
Stay updated withHemostasis Today.
-
Sep 16, 2026, 16:06Katrina Louise Manalaysay: In Your 20s, You Might be Given the Opportunity to Donate Blood for the First Time
-
Sep 16, 2026, 15:45Matthew Hazell: A Brilliant Explanation of Phenotype vs Genotype Using a LEGO House
-
Sep 16, 2026, 15:23Ahmad Al-Ramahi: Presenting the Military Pharmacists Blood Training Course at the FIP World Congress
-
Sep 16, 2026, 15:21HIT Reimagined: Can 12-Lipoxygenase Inhibition Stop Immune Thrombosis?
-
Sep 16, 2026, 14:42Ruchi Punamia: Beyond the Blood Bank and The Clinical Impact of Apheresis
-
Sep 16, 2026, 14:06Kalyan Roy: Celebrating Apheresis, Advancing Care, Saving Lives
-
Sep 16, 2026, 13:38Andrew Zapfel: Advancing Sickle Cell Disease Care and Research
-
Sep 16, 2026, 13:30Thirunavukkarasu Angappan: Why Plasma-Derived Factor VIII Still Matters for Inhibitor Patients
-
Sep 16, 2026, 13:22Matthew Hazell: New BSH Guidance for Fetal, Neonatal and Paediatric Transfusion